Together, these findings support CSDE1 as a key driver that enhances RAC1-mediated MAPK signaling and metabolic profiles in PCa, suggesting that CSDE1 may serve as a promising prognostic biomarker and therapeutic target. This evidence concerns the gene RAC1 and posterior cortical atrophy.